158 related articles for article (PubMed ID: 34694927)
1. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate.
Choi EJ; Xu P; Barham D; El-Khatib FM; Yafi FA; Kavoussi PK
J Urol; 2022 Mar; 207(3):677-683. PubMed ID: 34694927
[TBL] [Abstract][Full Text] [Related]
2. Post-market safety and efficacy profile of subcutaneous testosterone enanthate-autoinjector: a cohort analysis.
Choi EJ; Xu P; El-Khatib FM; Kavoussi PK; Yafi FA
Int J Impot Res; 2022 Aug; 34(5):467-470. PubMed ID: 34007063
[TBL] [Abstract][Full Text] [Related]
3. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
Gittelman M; Jaffe JS; Kaminetsky JC
J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
[TBL] [Abstract][Full Text] [Related]
4. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration.
Arora S; Moclair B; Murphy K; Jaffe JS; Kaminetsky JC
J Sex Med; 2018 Dec; 15(12):1707-1715. PubMed ID: 30393104
[TBL] [Abstract][Full Text] [Related]
5. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
6. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
7. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
Borst SE; Yarrow JF
Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
9. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
10. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
11. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
12. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
[TBL] [Abstract][Full Text] [Related]
13. The five-year effects of testosterone replacement therapy on lipid profile and glucose tolerance among hypogonadal men in Japan: a case control study.
Kato Y; Shigehara K; Nakashima K; Iijima M; Kawagushi S; Nohara T; Izumi K; Kadono Y; Konaka H; Namiki M; Mizokami A
Aging Male; 2020 Mar; 23(1):23-28. PubMed ID: 30651019
[No Abstract] [Full Text] [Related]
14. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Hematocrit Change in Testosterone-deficient Men Treated With Intranasal Testosterone Gel vs Intramuscular Testosterone Cypionate: A Randomized Clinical Trial.
Rivero MJ; Ory J; Diaz P; Thirumavalavan N; Han S; Reis IM; Ramasamy R
J Urol; 2023 Jul; 210(1):162-170. PubMed ID: 37126399
[TBL] [Abstract][Full Text] [Related]
16. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
[TBL] [Abstract][Full Text] [Related]
19. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
20. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
Int Braz J Urol; 2010; 36(6):700-7; discussion 707-9. PubMed ID: 21176276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
